Science / Alzheimer's disease FDA Advisers Quit Over Alzheimer's Drug: 'Sham Process' They're not happy the agency OK'd Biogen's Aduhelm against panel's recommendation By Jenn Gidman Posted Jun 10, 2021 9:25 AM CDT Copied Back